Cargando…

Validation of the new pathology staging system for progressive supranuclear palsy

Detalles Bibliográficos
Autores principales:	Briggs, Mayen, Allinson, Kieren Simon James, Malpetti, Maura, Spillantini, Maria Grazia, Rowe, James Benedict, Kaalund, Sanne Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043892/ https://www.ncbi.nlm.nih.gov/pubmed/33778920 http://dx.doi.org/10.1007/s00401-021-02298-z

Ejemplares similares

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity
por: Kaalund, Sanne Simone, et al.
Publicado: (2020)

Accurate digital quantification of tau pathology in progressive supranuclear palsy
por: Pansuwan, Tanrada, et al.
Publicado: (2023)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Structural correlates of survival in Progressive Supranuclear Palsy
por: Street, Duncan, et al.
Publicado: (2023)

Neuroinflammation predicts disease progression in progressive supranuclear palsy
por: Malpetti, Maura, et al.
Publicado: (2021)

Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
por: Street, Duncan, et al.
Publicado: (2021)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Progressive supranuclear palsy: diagnosis and management
por: Rowe, James B, et al.
Publicado: (2021)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
por: Smith, Ruben, et al.
Publicado: (2020)

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
por: Chouliaras, Leonidas, et al.
Publicado: (2022)

Managing cognition in progressive supranuclear palsy
por: Rittman, Timothy, et al.
Publicado: (2016)

[(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2018)

Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome
por: Whiteside, David J., et al.
Publicado: (2023)

Language impairment in progressive supranuclear palsy and corticobasal syndrome
por: Peterson, Katie A., et al.
Publicado: (2019)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer’s disease
por: Coughlin, David G., et al.
Publicado: (2022)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Co‐Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy
por: Kok, Zi Q., et al.
Publicado: (2021)

Structural and Functional Thalamic Changes in Progressive Supranuclear Palsy
por: Tan, Sean YW, et al.
Publicado: (2022)

Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome
por: Jabbari, Edwin, et al.
Publicado: (2020)

Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy()
por: Hughes, Laura E., et al.
Publicado: (2013)

Distribution patterns of tau pathology in progressive supranuclear palsy
por: Kovacs, Gabor G., et al.
Publicado: (2020)

Altered network stability in progressive supranuclear palsy
por: Whiteside, David J, et al.
Publicado: (2021)

Weight loss in the early stage of progressive supranuclear palsy
por: Tsuge, Ayako, et al.
Publicado: (2016)

Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy
por: Rittman, Timothy, et al.
Publicado: (2016)

A Longitudinal Study of Motor, Oculomotor and Cognitive Function in Progressive Supranuclear Palsy
por: Ghosh, Boyd C. P., et al.
Publicado: (2013)

Social cognitive deficits and their neural correlates in progressive supranuclear palsy
por: Ghosh, Boyd C. P., et al.
Publicado: (2012)

Neurophysiological consequences of synapse loss in progressive supranuclear palsy
por: Adams, Natalie E, et al.
Publicado: (2022)

Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)

Genetics of Progressive Supranuclear Palsy
por: Im, Sun Young, et al.
Publicado: (2015)

Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy
por: Shin, Chaewon, et al.
Publicado: (2018)

The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy
por: Jabbari, Edwin, et al.
Publicado: (2019)

Gait improvement after levofloxacin administration in a progressive supranuclear palsy patient
por: Kurihara, Masanori, et al.
Publicado: (2020)

Gene-Environment Interactions in Progressive Supranuclear Palsy
por: Litvan, Irene, et al.
Publicado: (2021)

Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance
por: Grimm, Max-Joseph, et al.
Publicado: (2020)

‘Hummingbird’ sign in progressive supranuclear palsy
por: Shukla, Rakesh, et al.
Publicado: (2009)

Clinical Approach to Progressive Supranuclear Palsy
por: Ling, Helen
Publicado: (2016)

Hummingbird sign in progressive supranuclear palsy
por: Verma, Rajesh, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_er4bok4th4l5j5pcfpfcefvagq